全文获取类型
收费全文 | 4032篇 |
免费 | 393篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 51篇 |
儿科学 | 178篇 |
妇产科学 | 64篇 |
基础医学 | 648篇 |
口腔科学 | 58篇 |
临床医学 | 462篇 |
内科学 | 829篇 |
皮肤病学 | 35篇 |
神经病学 | 254篇 |
特种医学 | 65篇 |
外科学 | 523篇 |
综合类 | 81篇 |
一般理论 | 13篇 |
预防医学 | 434篇 |
眼科学 | 40篇 |
药学 | 242篇 |
中国医学 | 3篇 |
肿瘤学 | 451篇 |
出版年
2023年 | 24篇 |
2022年 | 30篇 |
2021年 | 89篇 |
2020年 | 49篇 |
2019年 | 89篇 |
2018年 | 74篇 |
2017年 | 64篇 |
2016年 | 63篇 |
2015年 | 82篇 |
2014年 | 98篇 |
2013年 | 154篇 |
2012年 | 228篇 |
2011年 | 216篇 |
2010年 | 124篇 |
2009年 | 132篇 |
2008年 | 184篇 |
2007年 | 201篇 |
2006年 | 179篇 |
2005年 | 167篇 |
2004年 | 172篇 |
2003年 | 164篇 |
2002年 | 136篇 |
2001年 | 126篇 |
2000年 | 178篇 |
1999年 | 125篇 |
1998年 | 51篇 |
1997年 | 45篇 |
1996年 | 38篇 |
1995年 | 39篇 |
1994年 | 57篇 |
1993年 | 45篇 |
1992年 | 86篇 |
1991年 | 93篇 |
1990年 | 90篇 |
1989年 | 75篇 |
1988年 | 58篇 |
1987年 | 57篇 |
1986年 | 61篇 |
1985年 | 47篇 |
1984年 | 40篇 |
1983年 | 33篇 |
1982年 | 28篇 |
1981年 | 25篇 |
1979年 | 30篇 |
1978年 | 19篇 |
1977年 | 23篇 |
1971年 | 20篇 |
1969年 | 25篇 |
1968年 | 26篇 |
1966年 | 21篇 |
排序方式: 共有4431条查询结果,搜索用时 15 毫秒
71.
- DNA is the sequence that codes for proteins.
- Messenger RNA is transcribed from the DNA sequence of genes and translated into protein.
- It can be difficult to predict how a change in the DNA sequence will affect messenger RNA and protein quantity and quality.
- DNA translocation changes can cause the joining of sequences from two different genes or different parts of the same gene.
- DNA sequencing is often used clinically to predict how DNA changes might affect proteins.
- Alternatively, RNA sequencing can be used as a more direct measure of the effect of DNA changes on the protein products.
- This sequencing is important for identifying changes in cancer that may indicate response to targeted therapy, prognosis, or diagnosis.
72.
73.
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study 总被引:1,自引:0,他引:1
Noone PG Hamblett N Accurso F Aitken ML Boyle M Dovey M Gibson R Johnson C Kellerman D Konstan MW Milgram L Mundahl J Retsch-Bogort G Rodman D Williams-Warren J Wilmott RW Zeitlin P Ramsey B;Cystic Fibrosis Therapeutics Development Research Group 《Pediatric pulmonology》2001,32(2):122-128
Cystic fibrosis (CF) is characterized by defective cystic fibrosis transmembrane regulator (CFTR) expression and function, associated with abnormal ion transport and mucociliary clearance, and clinical lung disease. Triphosphate nucleotides such as uridine-5'-triphosphate (UTP) and INS 365, may be useful for CF through actions, mediated via P2Y(2) extracellular receptors, on chloride and liquid secretion, and ciliary beat frequency. INS 365 may offer chemical stability advantages over UTP. In a randomized, double-blind, multicenter phase I study, we studied the safety and maximally tolerated dose of escalating, single doses of aerosolized INS 365, in adult and pediatric patients with mild to moderate CF lung disease (FEV(1) > or = 45% predicted). In four successive dose cohorts of adult patients (n = 12 per cohort, age > or = 18 years) and four successive pediatric dose cohorts (n = 12 per cohort, age 5-12 years), patients were randomized 3:1 active/placebo (0.9% saline) to evaluate doses of 20, 40, 80, and 100 mg INS 365 delivered by nebulizer (Pari Star ). Sputum was collected pre- and post-dosing to obtain preliminary results on clinical efficacy. After each dose cohort, a Data Safety Monitoring Committee (DSMC) reviewed the data. Forty-eight adult and 36 pediatric patients completed the protocol (up to 100 mg for adults, 80 mg for pediatric patients). The predominant adverse events were cough, wheezing, chest tightness, and a decrease in FEV(1) (occurring in 8/48 adults, and 5/36 pediatric patients), which occurred predominantly in the 80-mg and 100-mg dose cohorts. Though a few adult patients had a tendency to increase sputum production, there was little consistent effect noted on sputum production in this acute, single-dose study. The data suggest that aerosolized INS 365 is safe when delivered at single doses of up to 40 mg in adults and children with CF, but that higher doses are unlikely to be tolerated. 相似文献
74.
75.
76.
77.
78.
Nuntra Suwantarat Mayer Rubin Latetia Bryan Tsigereda Tekle Michael P. Boyle Karen C. Carroll Mark T. Jennings 《Diagnostic microbiology and infectious disease》2018,90(4):296-299
Background
Small-colony variants (SCVs) are a distinct phenotype of Staphylococcus aureus, known for their role in chronic, difficult to treat infections, including cystic fibrosis (CF) lung disease. The goal of this study was to characterize SCV MRSA infection in an adult and pediatric CF population and to identify antibiotic susceptibility patterns unique to SCV MRSA.Methods
We recovered methicillin-resistant S. aureus (MRSA) from respiratory culture samples from CF patients at the Johns Hopkins Hospital during a 6 month study period.Results
Of 1161 samples, 200 isolates (17%) were identified as MRSA, and 37 isolates from 28 patients were identified as SCV MRSA. A higher proportion of MRSA was found among SCV isolates (37/66, 56%) compared to normal colony variant (NCV) isolates (163/417, 39%), p = 0.02. All SCV MRSA isolates from individual patients were susceptible to vancomycin and ceftaroline, but they demonstrated higher rates of antibiotic resistance to trimethoprim/sulfamethoxazole, moxifloxacin, and erythromycin, compared to NCV MRSA isolates. Additionally, individuals with SCV MRSA had lower lung function, higher rates of persistent MRSA infection, and higher rates of previous antibiotic use, compared to individuals with NCV MRSA.Conclusions
A significant proportion of MRSA isolates recovered from patients with CF have the SCV morphology. Compared to individuals with NCV MRSA, those with SCV MRSA have higher rates of persistent MRSA infection and lower lung function. SCV MRSA isolates were more resistant than NCV, but they are highly susceptible to vancomycin, linezolid and ceftaroline. 相似文献79.
C Peers J P Boyle J L Scragg M L Dallas M M Al-Owais N T Hettiarachichi J Elies E Johnson N Gamper D S Steele 《British journal of pharmacology》2015,172(6):1546-1556
Carbon monoxide (CO) is firmly established as an important, physiological signalling molecule as well as a potent toxin. Through its ability to bind metal-containing proteins, it is known to interfere with a number of intracellular signalling pathways, and such actions can account for its physiological and pathological effects. In particular, CO can modulate the intracellular production of reactive oxygen species, NO and cGMP levels, as well as regulate MAPK signalling. In this review, we consider ion channels as more recently discovered effectors of CO signalling. CO is now known to regulate a growing number of different ion channel types, and detailed studies of the underlying mechanisms of action are revealing unexpected findings. For example, there are clear areas of contention surrounding its ability to increase the activity of high conductance, Ca2+-sensitive K+ channels. More recent studies have revealed the ability of CO to inhibit T-type Ca2+ channels and have unveiled a novel signalling pathway underlying tonic regulation of this channel. It is clear that the investigation of ion channels as effectors of CO signalling is in its infancy, and much more work is required to fully understand both the physiological and the toxic actions of this gas. Only then can its emerging use as a therapeutic tool be fully and safely exploited.
Linked Articles
This article is part of a themed section on Pharmacology of the Gasotransmitters. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-6 相似文献80.